Natus Medical (Nasdaq: BABY) reported earnings on Nov. 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Natus Medical met expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share dropped to a loss.

Gross margins expanded, operating margins contracted, net margins dropped.

Revenue details
Natus Medical booked revenue of $80.7 million. The three analysts polled by S&P Capital IQ hoped for revenue of $81.4 million on the same basis. GAAP reported sales were 57% higher than the prior-year quarter's $51.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.07. The two earnings estimates compiled by S&P Capital IQ anticipated $0.14 per share. GAAP EPS were -$0.07 for Q3 compared to $0.01 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 54.8%, 110 basis points better than the prior-year quarter. Operating margin was -6.0%, 650 basis points worse than the prior-year quarter. Net margin was -2.4%, 270 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $95.9 million. On the bottom line, the average EPS estimate is $0.29.

Next year's average estimate for revenue is $296.1 million. The average EPS estimate is $0.60.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,256 members out of 1,287 rating the stock outperform, and 31 members rating it underperform. Among 361 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 351 give Natus Medical a green thumbs-up, and 10 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Natus Medical is hold, with an average price target of $13.50.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.